KWMG
HRTX icon

King Wealth Management Group’s Heron Therapeutics HRTX Stock Holding History

King Wealth Management Group’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14K Hold
32,799
– – ﹤0.01% 176
2026
Q1 		$26K Buy
32,799
+2,000
+6% +$2.32K ﹤0.01% 157
2025
Q4 		$40K Buy
30,799
+1,000
+3% +$1.24K ﹤0.01% 164
2025
Q3 		$38K Buy
29,799
+1,000
+3% +$1.59K ﹤0.01% 160
2025
Q2 		$60K Buy
28,799
+2,000
+7% +$4.08K 0.01% 157
2025
Q1 		$59K Hold
26,799
– – 0.01% 156
2024
Q4 		$41K Buy
26,799
+3,500
+15% +$5.67K 0.01% 154
2024
Q3 		$46K Buy
23,299
+8,000
+52% +$19.1K 0.01% 151
2024
Q2 		$54K Buy
15,299
+5,200
+51% +$16K 0.01% 142
2024
Q1 		$28K Buy
+10,099
New +$25.4K ﹤0.01% 147

Other funds holding HRTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
PFCS
Pale Fire Capital SE Prague, Czech Republic $1.41B AUM 25.22% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
CPC
Congress Park Capital Saratoga Springs, New York $370M AUM 26.01% 1-Year Est. Return

King Wealth Management Group's HRTX Position: Q2 2026 in Review

King Wealth Management Group held its Heron Therapeutics (HRTX) position steady in Q2 2026 at 32,799 shares worth $14K. The position accounts for ﹤0.01% of the portfolio, ranked #176.

King Wealth Management Group first reported a position in HRTX in Q1 2024 and has held it in 10 quarters since. The position peaked at $60K in Q2 2025. 120 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • King Wealth Management Group held 32,799 shares of Heron Therapeutics worth $14K as of Q2 2026.
  • King Wealth Management Group left its Heron Therapeutics share count unchanged in Q2 2026.
  • Heron Therapeutics made up ﹤0.01% of King Wealth Management Group's portfolio in Q2 2026, its #176 holding.
  • King Wealth Management Group first reported a position in Heron Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • King Wealth Management Group's Heron Therapeutics position peaked at $60K in Q2 2025.
  • 120 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on King Wealth Management Group's 13F filing for Q2 2026, filed 5 Aug 2026.